Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Pseudomyxoma Peritonei × Clear all

Phase

Phase 2 9 Phase NA 4 Phase 1 4 Phase 3 2 Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 153 Neoplasms 95 Prostatic Neoplasms 90 Multiple Myeloma 71 Pancreatic Neoplasms 68 Glioblastoma 65 Glioma 58 Brain Neoplasms 53 Lung Neoplasms 50 Head and Neck Neoplasms 46 Leukemia, Myeloid, Acute 44 Colorectal Neoplasms 44 Melanoma 43 Carcinoma, Hepatocellular 41 Ovarian Neoplasms 40 Carcinoma, Non-Small-Cell Lung 40 Squamous Cell Carcinoma of Head and Neck 39 Recurrence 36 Lymphoma 31 Stomach Neoplasms 30 Neoplasm Metastasis 30 Lymphoma, Non-Hodgkin 28 Lymphoma, B-Cell 28 Hematologic Neoplasms 27 Sarcoma 26 Solid Tumor 25 Precursor Cell Lymphoblastic Leukemia-Lymphoma 25 Carcinoma, Renal Cell 25 Burkitt Lymphoma 25 Polycystic Ovary Syndrome 24

Interventions

tislelizumab 1 molgramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07341360 2026-01-14

Pseudovax

Oslo University Hospital

Phase EARLY_PHASE1 Recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡